Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• HISHS-3001 is a novel, long-acting, tri-receptor agonist of gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.
• Diabetic db/db mice received subcutaneous HISHS-3001 at 3 or 20 nmol/kg every third day for 4 weeks, or tirzepatide (synthesized in-house).
• HISHS-3001 reduced HbA1c, body weight, triglycerides, and glucagon levels, and led to an increase in fibroblast growth factor-21 (FGF-21).
• In this animal model, the tri-agonist had higher effects on glucose homeostasis and metabolic biomarkers than dual GIP/GLP-1 receptor agonism.